The EXSCEL trial, which followed exenatide (another GLP-1 agonist) users for approximately three years across roughly 83,000 patient-years of follow-up, found no evidence that treatment increases serum calcitonin concentrations or risk of MTC in humans
A personalized treatment plan may include: progressive strengthening exercises physiotherapy flexibility and mobility training activity modification weight management where appropriate nutritional support regenerative therapies when clinically indicated regular follow-up to monitor progress For athletes, rehabilitation may emphasize restoring strength, balance, and sport-specific movement patterns before returning to competition
This means the FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they are marketed." (Source: FDA "Compounding and the FDA: Questions and Answers".) Clinical efficacy data such as the 14.9% mean weight loss from the STEP 1 trial or the 22.5% from SURMOUNT-1 comes from studies of the FDA-approved formulations, not from compounded versions
This changes the timing and the shape of the breath test curve patterns
Upon ligand binding, GLP-1R activation enhances glucose-dependent insulin secretion, suppresses glucagon release, delays gastric emptying, and reduces appetite, collectively improving glycemic control and promoting clinically meaningful weight reduction [19]
Risks rise sharply with unregulated providers or home use